ArticlebioRxiv : the preprint server for biology2025
A Benchmark of Semi-Supervised scRNA-seq Integration Methods in Real-World Scenarios.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
3 authors.
Funding
Abstract
Semi-supervised methods for single-cell RNA-seq integration promise to improve batch correction and biological signal preservation by leveraging cell-type labels. However, their reported benefits often rely on overly idealized settings. Here, we present the first systematic benchmark of five leading semi-supervised methods (scANVI, scGEN, ssSTACAS, scDREAMER, ItClust) against five widely used unsupervised baselines across six diverse datasets. We evaluate performance under five realistic annotation scenarios, including missing, erroneous, boundary-missing and mixed, batch-specific, and auto-generated labels, using nine established integration metrics. While semi-supervised methods show gains with perfect annotations, their robustness declines sharply under practical imperfections. Only scANVI and ssSTACAS maintain stable but modest improvements relative to their unsupervised counterparts, while none consistently outperform the strongest unsupervised method, scCRAFT. Our results highlight that current semi-supervised strategies offer limited practical advantage and that careful choice of integration method remains critical when label quality is uncertain.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.